EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach






Therapie 60(3): 243-248

HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach

The HIV (human immunodeficiency virus)/AIDS epidemic is of unprecedented gravity and is spreading rapidly, notably in the most disadvantaged regions of the world. The search for a preventive vaccine is thus an absolute priority. For over 10 years the ANRS (Agence Nationale de Recherches sur le SIDA) has been committed to an original programme combining basic science and clinical research.


Accession: 012135976

PMID: 16128266

DOI: 10.2515/therapie:2005031



Related references

Salmon-Céron, D.; Durier, C.; Desaint, C.; Cuzin, L.; Surenaud, M.; Hamouda, N.Ben.; Lelièvre, J-Daniel.; Bonnet, Bénédicte.; Pialoux, G.; Poizot-Martin, I.; Aboulker, J-Pierre.; Lévy, Y.; Launay, O., 2011: Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. French National Agency for Research on AIDS and Viral Hepatitis's HIV-LIPO-5 vaccine includes five HIV-1 peptides, containing multiple CD8 and CD4 T-cell epitopes and coupled to a palmitoyl tail. Whether HIV-LIPO-5 immunogenicity varies with...

Launay, O.; Surenaud, M.; Desaint, C.; Ben Hamouda, N.; Pialoux, G.; Bonnet, Bénédicte.; Poizot-Martin, I.; Gonzales, G.; Cuzin, L.; Bourgault-Villada, I.; Lévy, Y.; Choppin, J.; Durier, C., 2014: Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine 31(40): 4406-4415

Toth, I.; Moyle, P.M.; Simerska, P.; Fujita, Y.; Olive, C.; Good, M.F., 2009: Vaccine delivery: synthesis and investigation of a highly pure, multi-epitopic lipopeptide vaccine candidate. Advances in Experimental Medicine and Biology 611: 347-349

Fruth, U., 2009: Considerations regarding efficacy endpoints in HIV vaccine trials: executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise. HIV vaccines of the first generation are, in contrast to most currently licensed vaccines, unlikely to provide sterilizing immunity against infection with HIV. However, they are expected to exert a beneficial effect on the maintenance of CD4 T-cel...

Anonymous, 2009: Considerations regarding efficacy endpoints in HIV vaccine trials I Executive summary and recommendations of an expert consultation jointly organized by WHO, UNAIDS and ANRS in support of the Global HIV Vaccine Enterprise

Sepulveda, D., 1950: Preventive vaccinations in children; antiwhooping cough-diptheria vaccine; antidiphtheria vaccine. Revista Chilena de Pediatria 21(4): 170-5; Contd

Birthistle, K.; Benbow, A., 1998: New combined hepatitis A and B vaccine. New vaccine is an adjunct, not an alternative to preventive behaviours. Bmj 316(7140): 1317-1318

Verma, R.; Khanna, P.; Chawla, S., 2013: Influenza vaccine: an effective preventive vaccine for developing countries. The Influenza virus A, B and C causes disease in humans, birds and animals. The Influenza type A causes moderate to severe illness in all age groups in humans while the illness caused by type B is of milder and it is primarily affects children. Am...

Gilbert, P.B.; Peterson, M.L.; Follmann, D.; Hudgens, M.G.; Francis, D.P.; Gurwith, M.; Heyward, W.L.; Jobes, D.V.; Popovic, V.; Self, S.G.; Sinangil, F.; Burke, D.; Berman, P.W., 2005: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. Background. An objective of the first efficacy trial of a candidate vaccine containing recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein 120 (rgp120) antigens was to assess correlations between antibody responses to rgp12...

Choi, D-Han.; Woo, J.Kyu.; Choi, Y.; Seo, H-Sook.; Kim, C-Woo., 2011: A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene. Intensive efforts to improve vaccines against cancer are currently outgoing. Mucin 1 (Muc1) is a tumor-specific antigen that is overexpressed and heavily glycosylated in a variety of adenocarcinomas. In the present study, the efficacy of an antica...